Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Indications/Uses

TAGRISSO (osimertinib) is indicated for: the adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations; the first-line treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations; the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Tagrisso Indications/Uses

Manufacturer:

AstraZeneca

Distributor:

DKSH